Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Mylan gets tentative...

    Mylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug Alimta

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-31T09:30:05+05:30  |  Updated On 16 Aug 2021 2:57 PM IST

    Alimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.


    U.S: The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly & Co's lung cancer drug Alimta.


    A tentative approval generally signals that the FDA has signed off on the company's marketing application, but that it cannot sell the medicine until the U.S. patents have expired.


    Lilly stands to lose U.S. patent protection on the chemotherapy drug, known generically as pemetrexed, in 2022.


    Read Also: Novo Nordisk files suit against Mylan to block entry of generic Victoza drug in US


    Earlier this month, Lilly won a federal appeals court decision protecting its patent from copycat drugs by Pfizer Inc and India's Dr Reddy's Laboratories Ltd.


    Read Also: Lawmakers push Mylan, Teva Pharma over drug pricing probe


    Alimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.


    Read Also: Biocon, Mylan launch biosimilar Ogivri for treatment of breast, stomach cancer in Australia

    AlimtacancerchemotherapyDr Reddy'sDr Reddy's LabsEli LillyLillyMylanPemetrexedPfizerpharmapharma companypharma newsreddyUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok